InterMed's novel Hif-1 cancer drug shows proof-of-principle
Dortmund, Germany-based InterMed Discovery GmbH, an emerging natural-product lead-discovery firm, says it has established proof-of-principle in a preclinical study of its optimized leading compound, IMD-026260, a cancer drug candidate.
The agent is a fully-synthetic small-molecule derived from a natural product lead compound that displays an "outstanding" cytotoxic potential, according to the firm, and exhibits a long half-life. IMD-026260 appears to be an inhibitor of Hypoxia-inducible factor 1 dependent transcriptional activity. Hif-1 activates the transcription of genes that are involved in crucial aspects of cancer biology, including angiogenesis, glucose metabolism, cell survival and invasiveness.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze